Cationic Nanoparticles for Cancer Chemotherapy
Conference Recording May 01, 2013
About the SpeakerErem Bilensoy graduated from Hacettepe University Faculty of Pharmacy in 1992. She received her M.Sc. degree on Pharmaceutical Technology with her thesis on the in vitro/in vivo evaluation of recombinant human Granulocyte Macrophage-Colony Stimulating Factor loaded niosome, emulsion and liquid crystal formulations for wound healing in the same university. She obtained her double Ph.D. degree with a co-tutelle thesis between Université Paris-Sud, France and Hacettepe University in 2002 on the evaluation of amphiphilic ß-cyclodextrins modified on the primary face as novel excipients in the preparation of nanospheres and nanocapsules. Erem Bilensoy worked as assistant professor between 2005-2007 and received her Associate Professor title in 2007. She is currently continuing her research work at the Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University. Abstract
Nanoparticles are promising delivery systems for the local or systemic application of anticancer drugs and active molecules with bioavailability problems. As a result of their favourable size distribution, nanoparticles can be targeted to tumor tissues via the Enhanced Permeation and Retention (EPR) Effect. In this sense, active targeting of anticancer drugs may also be achieved by surface modification of the nanoparticles. Positive surface charge affects the intracellular drug delivery and cellular uptake of nanoparticles due to improved interaction with biological membranes. Potential of cationic nanoparticles will be discussed in view of in vitro, cell culture and in vivo data.